Libman-Sacks endocarditis

Article written and reviewed by Dr Luca Moretti

Libman-Sacks endocarditis is a non-infective endocardial manifestation in which immune-mediated injury, thrombotic deposition, and fibrous repair mainly involve the mitral and aortic valves. It is chiefly associated with systemic lupus erythematosus and may occur within the spectrum of antiphospholipid syndrome, even without clinically recognized lupus. Lesions include sterile verrucous vegetations, leaflet thickening and deformation, chordal involvement, and, in organized forms, persistent valvular disease. The term should not be applied to every valvular insufficiency in a patient with lupus: degeneration, prolapse, ischemia, chamber dilation, and infective endocarditis remain possible and require their own diagnosis.
The clinical significance of the lesion depends on two properties that do not necessarily progress together: embolic potential and alteration of valvular function. Inconspicuous vegetations may be associated with cerebral events, whereas a fibrotic mitral apparatus may cause significant regurgitation even when an active vegetating mass is no longer evident.

Reported frequency varies according to the population, duration of lupus, and investigative method. Autopsy studies and studies using transesophageal echocardiography identify lesions that may escape transthoracic assessment or remain asymptomatic; percentages derived from these settings should not be interpreted as prevalence in the general population of patients with lupus. Antiphospholipid antibody positivity, a thrombotic history, and more severe systemic disease may be associated with greater valvular involvement, but are not indispensable conditions for diagnosis. Detection of a suspicious lesion should therefore prompt a combined cardiologic, rheumatologic, and thrombotic assessment, while keeping the infectious alternative open, particularly in immunosuppressed patients.

Etiology, pathogenesis, and pathophysiology

The initial process involves the endothelial surface and valvular connective tissue. In lupus, deposition of immune complexes, complement activation, and recruitment of inflammatory cells can produce endothelial injury and matrix alteration. Exposure of thrombogenic surfaces promotes platelet adhesion and fibrin accumulation, forming vegetations that combine immune-inflammatory and thrombotic components. The term endocarditis therefore denotes a sterile pathologic process and does not imply the presence of microorganisms. The intensity of the inflammatory component is not uniform and changes over time: a lesion observed during a systemic flare and a valvular scar present for years may belong to the same pathologic history but require different therapeutic interpretations.

Antiphospholipid antibodies can amplify the process through interaction with proteins bound to cell surfaces, activation of endothelium, monocytes, platelets, and complement, and increased expression of procoagulant signals. Beta2-glycoprotein I is a relevant target in this system; pathogenicity, however, cannot be reduced to the presence of any positive antibody result. Profile, titer, and persistence contribute to risk assessment together with clinical history. Triple positivity for lupus anticoagulant, anticardiolipin, and anti-beta2-glycoprotein I identifies a high-risk profile, but by itself does not prove that a valvular mass is Libman-Sacks endocarditis. Likewise, isolated and transient positivity during an infection is not equivalent to antiphospholipid syndrome.

Vegetations may be located on both leaflet surfaces, on the chordae, or on other endocardial regions. This distribution, together with thickening of the attachment base and involvement of the subvalvular apparatus, is suggestive but not pathognomonic. Active lesions may include fibrin, platelets, necrotic material, and inflammatory infiltrates; later phases show organization, neovascularization, and fibrosis. Repeated deposition and repair can thicken and retract the leaflets, shorten or alter the chordae, and reduce their mobility. Overlap of different phases in the same valve explains why morphology cannot be read as a direct measure of current lupus activity.

The mitral valve is frequently involved, followed by the aortic valve; right-sided involvement is possible but less usual. Mitral regurgitation may result from imperfect coaptation of thickened or retracted leaflets and chordal abnormalities. More extensive fibrosis may also restrict opening, but stenosis should not automatically be attributed to Libman-Sacks without considering other etiologies. When regurgitation persists, volume overload causes atrial and ventricular dilation; increased filling pressures are transmitted to the pulmonary circulation and may lead to congestion. Ejection fraction must be interpreted in the context of regurgitation, because ejection toward a low-impedance atrium can mask reduced myocardial performance.

Detachment of material from left-sided vegetations causes systemic emboli. The presence of antiphospholipid antibodies adds a second mechanism: thrombosis may form directly in an artery or in the microcirculation without originating from the valve. In lupus, accelerated atherosclerosis, atrial fibrillation, hypertension, renal disease, and other conditions further contribute to cerebrovascular risk. Therefore, the association between vegetation and stroke should not become automatic attribution of every cerebral lesion to cardioembolism. Neurologic injury may be multifactorial, and distinguishing embolism, local thrombosis, and neuroinflammatory manifestations is crucial to avoid both unjustified immunosuppression and insufficient antithrombotic prevention.

The relationship between immunologic activity and valvular damage is not linear. Effective control of lupus can reduce an inflammatory stimulus and favor improvement of a recent component, but does not necessarily eliminate established fibrous deformity. Conversely, an apparently stable vegetation may retain embolic significance in the presence of persistent hypercoagulability. Pathophysiologic assessment must therefore separate active inflammation, thrombosis, and structural damage: these are three related dimensions, but no single biomarker or echocardiographic finding represents them all.

The concept of cumulative damage is particularly relevant in Libman-Sacks endocarditis. Healing of repeated episodes may incorporate thrombotic material into the leaflet surface and alter its flexibility; residual deformation in turn changes the distribution of mechanical stresses and may favor new deposition. The sequence is not necessarily identical in every patient and does not permit every thickening to be considered a healed vegetation. It does, however, explain why assessment based only on markers of current activity may underestimate the accumulated anatomic burden. Therapeutically, control of the cause limits new damage, whereas correction of an established mechanical defect may require an independent valve strategy.

Complement activation links immunity and thrombosis through several steps: activation products promote leukocyte recruitment and alter the function of cell surfaces, contributing to a proinflammatory and procoagulant environment. Local deposition and systemic consumption do not necessarily coincide, however. Reduced C3 or C4 may support the overall assessment of lupus but does not localize the process to the valve and does not quantify vegetation fragility. This dissociation between biologic mechanism and clinical measurability makes combined use of laboratory testing, imaging, and observation of events necessary rather than reliance on a single surrogate marker.

Clinical manifestations

The history begins with lupus and possible antiphospholipid syndrome: onset, flares, renal or neurologic involvement, cytopenias, mucocutaneous and articular manifestations, documented thromboses, and obstetric history. The temporal relationship among systemic activity, appearance of the valvular lesion, and embolic events should be reconstructed. Immunomodulatory therapy, cumulative steroid exposure, adherence to hydroxychloroquine, and antithrombotic treatments help interpret both the disease and infectious and iatrogenic risks. A vegetation discovered for the first time is not necessarily newly formed: comparison with previous echocardiograms may clarify whether it represents progression, a stable finding, or better visualization.

The search for neurologic manifestations should include sudden focal deficits, transient episodes, visual disturbances, speech abnormalities, cognitive difficulties, and functional changes reported by the patient or family. Embolic forms may present with a major event or with repeated, less conspicuous lesions. Headache, seizures, and confusion instead have a broader differential diagnosis and do not by themselves identify vasculitis or inflammatory neuropsychiatric lupus. Flank pain, hematuria, acute abdominal pain, limb ischemic symptoms, or chest pain require consideration of other embolic and thrombotic territories.

Exertional dyspnea, orthopnea, reduced activity tolerance, and palpitations suggest a hemodynamic or arrhythmic consequence, but in lupus they may also result from anemia, myocarditis, pericarditis, pulmonary hypertension, nephropathy, or thromboembolism. Chronology and relationship with exertion help select investigations. In chronic valvular disease, spontaneous reduction in activity may mask worsening functional capacity: comparing concrete activities over time is useful rather than limiting assessment to a generic question about dyspnea. Symptom severity should not be inferred solely from vegetation size.

The search for concomitant infection remains an integral part of the history. Fever, chills, recent procedures, skin lesions, dental infections, vascular access, and antibiotics taken should be documented. Immunosuppression can blunt fever and the inflammatory response; improvement after glucocorticoids does not exclude infection. A previous diagnosis of Libman-Sacks likewise does not protect against infective endocarditis and does not justify automatically attributing every new febrile episode to lupus.

Physical examination initially assesses vital signs, perfusion, neurologic status, and signs of peripheral ischemia. Auscultation looks for regurgitation and changes from known findings, while venous pressure, crackles, edema, and hepatomegaly contribute to assessment of congestion. A mild or absent murmur does not exclude an emboligenic vegetation. Skin and mucosal examination looks for lupus manifestations, livedo, and possible vascular or infectious lesions without assigning each finding a specificity it does not possess. General assessment includes possible foci, signs of anemia, and clues to organ activity. A repeatable objective description makes it possible to distinguish a true change from fluctuation in nonspecific symptoms.

Investigations and diagnosis

Diagnosis is based on the association of compatible valvular findings, an autoimmune context, and reasonable exclusion of alternatives, especially infective endocarditis. There are no universally validated clinical criteria that diagnose Libman-Sacks simply by adding lupus, an echocardiographic mass, and negative cultures. The differential diagnosis also includes neoplastic NBTE, fibroelastoma, Lambl's excrescences, degeneration, and other causes of regurgitation. Pretest probability changes with context: a mass in a patient with lupus and persistent bacteremia requires a different interpretation from stable thickening found incidentally without signs of infection.

Transthoracic echocardiography documents anatomy, valve function, and chamber consequences; transesophageal echocardiography further evaluates small lesions, equivocal findings, and suspected embolic sources when the result can change management. In dedicated studies, transesophageal echocardiography has shown greater ability to detect and characterize lesions, but this does not automatically justify repeated invasive screening in every patient with lupus. Three-dimensional reconstruction can better define distribution on leaflet surfaces, attachment base, extent, and relationships with commissures and chordae. It does not replace two-dimensional and Doppler assessment and does not by itself demonstrate the autoimmune nature of a mass.

The report should distinguish vegetation, thickening, and deformity, specifying mobility, dimensions, location, and alteration of coaptation. Quantification of regurgitation requires an integrated approach using Doppler parameters and hemodynamic consequences, avoiding reliance on a single sign. Perforations, abscesses, and other lesions that would strengthen suspicion of infection should be sought. During follow-up, small changes must be interpreted in relation to image quality and measurement reproducibility: an apparent difference of a few millimeters does not necessarily demonstrate biological growth or regression.

When infection is plausible, adequate blood cultures are obtained before antibiotics and previous antimicrobial exposure is reconstructed. Negative cultures are insufficient, especially after treatment or with difficult-to-culture pathogens. The blood culture-negative endocarditis pathway considers targeted serology and molecular methods, including those for Coxiella burnetii and Bartonella spp. when indicated by the clinical picture. Duke-ISCVID criteria help classify infective endocarditis, but they are not criteria for Libman-Sacks and do not support automatic reasoning by exclusion. Immunosuppression can modify presentation and increase the clinical cost of an etiologic error.

Complete blood count, platelet count, creatinine, urinalysis, and proteinuria describe systemic involvement and influence treatment safety. Complement and anti-double-stranded DNA antibodies may support assessment of lupus activity, but do not directly measure valvular inflammation. Active serology does not prove that a stable valvular scar requires more immunosuppression; minimally changed values do not exclude an embolic source. Erythrocyte sedimentation rate and C-reactive protein likewise have contextual value and do not infallibly distinguish autoimmune flare from infection.

The antiphospholipid panel includes lupus anticoagulant, anticardiolipin, and anti-beta2-glycoprotein I. Results must be interpreted considering isotype, titer, methodology, and persistence in samples separated by at least twelve weeks. Anticoagulants can interfere particularly with lupus anticoagulant testing; a test obtained during therapy requires interpretation agreed with the laboratory, without unjustified interruption of necessary treatment. The paradox of a prolonged aPTT in a thrombotic patient reflects lupus anticoagulant interference with phospholipid-dependent tests and does not by itself demonstrate a protective anticoagulant effect in vivo.

The 2023 ACR/EULAR criteria include a valvular domain among manifestations considered in classification of antiphospholipid syndrome. Their purpose is to select research populations with high specificity by combining an entry criterion with weighted clinical and laboratory domains. They are therefore classification criteria, not a substitute diagnostic algorithm: a vegetation alone does not diagnose the syndrome, and failure to reach a classification threshold does not eliminate every possible clinical significance of the antibodies. A lesion more plausibly explained by infection or another cause should also not be counted as an antiphospholipid manifestation.

In the presence of a neurologic event, CT, vascular imaging, and brain MRI are selected according to urgency and the diagnostic question. Distribution of infarcts, any hemorrhage, and vascular disease help distinguish embolization, local thrombosis, and other conditions. Rhythm monitoring and evaluation of additional embolic sources complete attribution. Transcranial Doppler can document microembolic signals in specialist and research settings, but is not required for diagnosis of Libman-Sacks endocarditis. Further investigations for neuroinflammation or vasculitis should be justified by the clinical picture, not initiated simply because the patient has lupus and a cerebral lesion.

If surgical tissue is available, histologic assessment looks for inflammatory activity, thrombi, organization, and fibrosis; microbiology and appropriate methods help exclude microorganisms. The description should be compared with treatments received and with echocardiographic morphology. Reduction of a vegetation during immunomodulatory and antithrombotic treatment can support the clinical interpretation, but does not identify which therapeutic component acted or retrospectively exclude all alternatives. The most useful diagnostic result is not merely a name: it is definition of the potentially reversible component, thrombotic risk, and mechanical damage that has already become established.

Hemodynamic assessment should be performed under known conditions of blood pressure, heart rate, and loading, because the apparent severity of regurgitation also varies with these factors. An eccentric jet adhering to the atrial wall may be underestimated if only its area is considered; orifice geometry, vena contracta, Doppler signals, and chamber consequences should be interpreted together. Serial comparison should look not only for worsening of the jet but also for dilation, changes in function, and increased pulmonary pressures. Apparent stability of the vegetation therefore does not exclude progression of the hemodynamic consequence, which may become the dominant problem.

The renal differential diagnosis illustrates the risk of excessive attribution to lupus. Hematuria and worsening function may result from nephritis, embolic infarction, thrombosis or antiphospholipid microangiopathy, infection, or drug toxicity. Sudden flank pain and lesion distribution on imaging favor ischemia, whereas urinary sediment and proteinuria contribute to glomerular assessment; no isolated finding is sufficient for all alternatives. Even known renal involvement may overlap with a new mechanism. Identifying which component is progressing changes both therapy and interpretation of bleeding risk and drug exposure.

Echocardiographic definitions used in studies must be distinguished from universal clinical thresholds. Research on Libman-Sacks uses operational criteria for dimensions, echogenicity, and location to make readings comparable; a mass below a protocol threshold is not thereby clinically meaningless, and one above the same threshold is not automatically autoimmune. Interobserver agreement likewise measures reproducibility of a classification, not certainty of etiology. In clinical reporting, an accurate anatomic description and reasoned probabilistic interpretation are therefore preferable to simple transcription of a research definition.

Treatment and prognosis

Therapy addresses three distinct goals: control of autoimmune disease, prevention of thromboembolic events, and correction of valvular dysfunction. There is no specific immunosuppressive regimen supported by large randomized studies in Libman-Sacks endocarditis. Recommendations for lupus and antiphospholipid syndrome provide the general reference; studies directly addressing the valvular lesion are mainly observational. The choice should therefore distinguish what is recommended for systemic disease from what is only associated with improvement of vegetations in small series.

Hydroxychloroquine is generally recommended in lupus unless contraindicated. EULAR recommendations indicate a target dose of 5 mg/kg of actual body weight per day, individualized according to disease activity and retinal risk. Ophthalmologic monitoring and assessment of factors increasing toxicity, including renal dysfunction, are part of management. The drug contributes to systemic control and may have favorable effects on thrombotic risk, but it is not a substitute for anticoagulation in thrombotic antiphospholipid syndrome and should not be described as an agent capable of directly dissolving the vegetation.

Glucocorticoids and other immunomodulators are selected according to the organs involved and severity of lupus. During active phases, intensive treatment may be necessary, whereas maintenance strategy aims to reduce prednisone equivalent to no more than 5 mg/day and, when possible, discontinue it. This general objective does not constitute a stand-alone regimen for the valve. The choice of immunosuppressants or biologics should be justified by systemic disease and a plausible inflammatory component; there is no evidence that increasing immunosuppression corrects a fibrotic, retracted leaflet. Before intensifying treatment, the possibility of infection should be reassessed, particularly with fever, rapid growth of the mass, or new destructive signs.

In the reassessment study published by Roldan and colleagues in 2021, 17 patients with Libman-Sacks endocarditis and cerebrovascular disease were reevaluated after a median of six months of clinically guided anti-inflammatory and antithrombotic therapy. Thirteen showed improvement or resolution of vegetations or regurgitation, whereas reduction in valvular thickening was not statistically significant. This difference is consistent with the possibility of a reversible component alongside more organized damage, but does not demonstrate the mechanism in an individual case. The nonrandomized design, cohort selection, and treatment heterogeneity prevent attribution of the result to a single drug. Reassessment after medical treatment is reasonable in stable conditions, without delaying surgery required for hemodynamic instability.

Secondary prevention in thrombotic antiphospholipid syndrome is usually based on vitamin K antagonists. After a first venous thrombosis, the usual target is INR 2–3; after arterial thrombosis, recommendations contemplate INR 2–3 or 3–4 according to individual risk. Recurrence first requires verification of adherence, the actual time spent in therapeutic range, and other causes of the event. Only then are intensification, possible addition of an antiplatelet agent, or switching to heparin in selected settings discussed. These decisions concern prevention of thrombosis and should not be confused with proof of efficacy on anatomic regression of the vegetation.

In the TRAPS trial, conducted in high-risk triple-positive patients with antiphospholipid syndrome, rivaroxaban showed unfavorable outcomes compared with warfarin. The finding did not arise from a valve-specific comparison, but is directly relevant to anticoagulant choice for this profile. Rivaroxaban should not be considered equivalent in this scenario, and direct oral anticoagulants are not the reference choice in the syndrome with arterial events. Ease of administration does not compensate for the absence of demonstrated adequate protection in the appropriate population.

An incidental vegetation without previous thrombosis does not create a universal indication for anticoagulation. The antiphospholipid profile, lesion characteristics, other thrombotic factors, and bleeding risk should be considered; low-dose aspirin is indicated in specific high-risk profiles according to syndrome recommendations, but is not equivalent to treatment of a thrombotic form. After stroke, starting or resuming anticoagulation depends on the extent of ischemia, the hemorrhagic component, and residual probability of infection. During pregnancy, thrombotic and obstetric history guide use of heparin and aspirin in the indicated settings, with planning that includes delivery and the puerperium; treatment cannot simply be transferred unchanged from the preconception phase.

Valve surgery is discussed for severe regurgitation with symptoms or significant cardiac consequences and for recurrent embolization despite appropriate therapy, after assessing the source of the events. Repair may be possible when damage is limited and residual tissue permits durable reconstruction; diffuse fibrosis, retraction, and subvalvular involvement may require replacement. The small available series do not demonstrate universal superiority of mechanical or bioprosthetic valves. Age, future pregnancy, renal function, an independent need for anticoagulation, bleeding risk, and possibility of future interventions must be considered together. Surgery corrects a mechanical problem but does not eliminate lupus or hypercoagulability.

Prognosis depends on neurologic injury, valvular and ventricular function, nephropathy, and systemic activity. A reduced vegetation does not guarantee recovery of an established cerebral deficit, whereas stable residual thickening does not necessarily demonstrate ongoing active disease. Follow-up therefore tracks three trajectories: autoimmune activity, thromboembolic risk, and structural consequences. Echocardiography, clinical assessment, and drug safety are scheduled according to these trajectories, without a single interval valid for everyone. Stability also requires continuity of anticoagulation monitoring and coordination of procedures that might interrupt it.

Immunomodulatory choice requires particular attention to distinguishing neuroinflammatory from thrombotic manifestations. An ischemic stroke with a plausible embolic source is not, by itself, proof of cerebral vasculitis and does not automatically justify increased immunosuppression. Conversely, another active organ manifestation, such as nephritis, may require specific therapy even if the vegetation is stable. The plan should therefore not be built around the valvular image alone: activity, damage, and thrombotic risk are measured with different tools and can evolve in different directions. The goal is to avoid both undertreatment of systemic disease and toxicity not offset by benefit.

In the event of hemorrhage or thrombocytopenia, the antithrombotic balance is not reduced to choosing between maintaining therapy and permanently stopping it. The site and severity of bleeding, reversibility of the cause, indication for anticoagulation, and recurrence risk during interruption should be defined. Immune thrombocytopenia may coexist with high thrombotic risk; platelet count should be interpreted with the clinical course and any signs of microangiopathy or consumption. In patients taking vitamin K antagonists, interactions, dietary changes, and adherence require continuous monitoring. The presence of lupus anticoagulant can make some monitoring methods problematic and requires collaboration with the laboratory when results do not fit the clinical picture.

Surgical planning also includes the likelihood that repair will remain durable in the presence of diffusely diseased tissue. A technically feasible reconstruction is not always the best solution if retraction and thickening involve multiple components; conversely, replacement is not mandatory solely because of the disease name when anatomy is favorable. After surgery, rheumatologic and antithrombotic management remains necessary, and excised specimens permit pathologic and microbiologic verification. Outcome should be measured by survival, function, embolic events, and quality of life, not merely by echocardiographic disappearance of the vegetation.

Complications

Embolic stroke may be the first manifestation of the valvular lesion and may recur, producing motor, sensory, visual, or language deficits and cognitive decline. Severity is not proportional to the murmur and cannot be inferred from a single measurement of vegetation size. With new symptoms, a new ischemic event should be distinguished from hemorrhage, edema from a previous infarct, seizure, or another lupus manifestation. In antiphospholipid syndrome, vascular thrombosis may coexist with valvular embolism: surgical correction of the valve therefore does not eliminate every possible cerebrovascular mechanism.

Extracerebral emboli may involve the kidneys, spleen, intestine, coronary arteries, and limbs. Renal infarction may be confused with nephritis or another renal disorder, while abdominal pain may be improperly attributed to serositis or vasculitis. Recognizing the site and mechanism is necessary to identify emergencies requiring revascularization. Rapid multiorgan deterioration in antiphospholipid syndrome should also prompt consideration of catastrophic APS with diffuse thrombosis, in addition to infection and other microangiopathies: not every simultaneous organ failure is explained by detachment of valvular fragments.

Chronic valvular disease may persist after immunologic activity is controlled. Fibrosis, retraction, and chordal abnormalities maintain regurgitation, favoring chamber dilation, pulmonary hypertension, and heart failure. Atrial dilation may contribute to development of arrhythmias, which add another embolic source or worsen hemodynamic tolerance. Surveillance should therefore focus not only on the presence of vegetation but also on volumes, ventricular function, pressures, and functional capacity. Waiting for an obvious reduction in ejection fraction may underestimate deterioration that is already clinically significant.

Superimposed infective endocarditis completely changes the strategy. An abnormal valve, immunosuppression, vascular access, and procedures may contribute to risk; new fever, bacteremia, rapid growth, or destructive lesions require reassessment. A positive blood culture cannot be considered contamination solely because the mass had previously been defined as sterile. Oral hygiene and care of infectious foci are relevant preventive measures, whereas antibiotic prophylaxis follows the risk categories and procedures defined in guidelines: the diagnosis of Libman-Sacks alone does not justify indiscriminate extension.

Treatment exposes patients to bleeding and toxicity. Thrombocytopenia, renal failure, and combined antithrombotic therapy increase hemorrhagic risk; infection and glucocorticoid-related harm may limit immunosuppression. After surgery, prosthetic thrombosis, emboli, hemorrhage, and deterioration of the repair or prosthesis are possible. Persistence of autoimmune disease and the procoagulant state may contribute to events, but surgical series are too small to quantify risk uniformly. Neurologic rehabilitation, education regarding planned treatment interruptions, and coordination among specialists are part of complication prevention, because the effectiveness of a strategy also depends on continuity over time.